Pfizer (PFE) Profit After Tax (2009 - 2026)

Pfizer (PFE) has reported Profit After Tax for 18 consecutive years, with -$248.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Profit After Tax fell 108.47% year-over-year to -$248.0 million in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 69.99% decrease from a year earlier, with the FY2025 full-year figure at $7.8 billion, down 3.1% from the prior year.
• Profit After Tax was -$248.0 million for Q2 2026 at Pfizer, down from $2.7 billion in the prior quarter.
• Over five years, Profit After Tax peaked at $9.9 billion in Q3 2022 and troughed at -$1.6 billion in Q4 2025.
• A 5-year average of $3.2 billion and a median of $2.9 billion in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax soared 187.34% in 2025 and sank 108.47% in 2026, its largest moves.
• Over 5 years, Profit After Tax stood at $225.0 million in 2022, then plunged by 73.33% to $60.0 million in 2023, then jumped by 12640.0% to $7.6 billion in 2024, then slumped by 121.45% to -$1.6 billion in 2025, then jumped by 84.88% to -$248.0 million in 2026.
• The last three Profit After Tax figures came in at -$248.0 million (Q2 2026), $2.7 billion (Q1 2026), and -$1.6 billion (Q4 2025), per Business Quant data.